Agnieszka K. Witkiewicz

Agnieszka K. Witkiewicz

Auto-generated profile, based on publicly available information

Agnieszka K. Witkiewicz

Univ Texas SW, Dept Pathol, Dallas, TX 75390 USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
APAmy R Peck
Amy R Peck
AWAgnieszka K Witkiewicz
Agnieszka K Witkiewicz
CLChengbao Liu
Chengbao Liu
AKAlexander C Klimowicz
Alexander C Klimowicz
GSGinger A Stringer
Ginger A Stringer
HRHallgeir Rui
Hallgeir Rui
Introduction: Signal transducer and activator of transcripton-5a (Stat5a) and its close homologue, Stat5b, mediate key physiological effects of prolactin and growth hormone in mammary glands. In breast cancer, loss of nuclear localized and tyrosine phosphorylated Stat5a/b is associated with poor prognosis and increased risk of antiestrogen therapy failure. Here we quantify for the first time levels of Stat5a and Stat5b over breast cancer progression, and explore their potential association with clinical outcome. Methods: Stat5a and Stat5b protein levels were quantified in situ in breast-cancer progression material. Stat5a and Stat5b transcript levels in breast cancer were correlated with clinical outcome in 936 patients. Stat5a protein was further quantified in four archival cohorts totaling 686 patients with clinical outcome data by using multivariate models. Results: Protein levels of Stat5a but not Stat5b were reduced in primary breast cancer and lymph node metastases compared with normal epithelia. Low tumor levels of Stat5a but not Stat5b mRNA were associated with poor prognosis. Experimentally, only limited overlap between Stat5a- and Stat5b-modulated genes was found. In two cohorts of therapy-naïve, node-negative breast cancer patients, low nuclear Stat5a protein levels were an independent marker of poor prognosis. Multivariate analysis of two cohorts treated with antiestrogen monotherapy revealed that low nuclear Stat5a levels were associated with a more than fourfold risk of unfavorable outcome. Conclusions: Loss of Stat5a represents a new independent marker of poor prognosis in node-negative breast cancer and may be a predictor of response to antiestrogen therapy if validated in randomized clinical trials.

4 December 2012 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
EKErik S. Knudsen
Erik S. Knudsen
TPThomas F. Pajak
Thomas F. Pajak
MQMaria Qeenan
Maria Qeenan
AMA. Kathleen McClendon
A. Kathleen McClendon
BABenjamin D. Armon
Benjamin D. Armon
AWAgnieszka K. Witkiewicz
Agnieszka K. Witkiewicz
A subset of patients with ductal carcinoma in situ (DCIS) will progress to invasive breast cancer. However, there are currently no markers to differentiate women at high risk from those at lower risk of developing invasive disease. The association of two major tumor suppressor genes, retinoblastoma (RB) and phosphatase and tensin homolog (PTEN), with risk of any ipsilateral breast event (IBE) or progression to invasive breast cancer (IBC) was analyzed using data from 236 DCIS patients treated with breast conserving surgery with long-term follow-up. RB and PTEN expression was assessed with immunohistochemistry. The functional effects of RB and/or PTEN loss were modeled in MCF10A cells. Hazard ratios (HRs) were estimated with univariate and multivariable Cox regression models. All statistical tests were two-sided. Loss of RB immunoreactivity in DCIS was strongly associated with risk of IBE occurrence (HR = 2.64; 95% confidence interval [CI] = 1.64 to 4.25) and IBC recurrence (HR = 4.66; 95% CI = 2.19 to 9.93). The prognostic power of RB loss remained statistically significant in multivariable analyses. PTEN loss occurred frequently in DCIS but was not associated with recurrence or progression. However, patients with DCIS lesions that were both RB and PTEN deficient were at further increased risk for IBEs (HR = 3.39; 95% CI = 1.92 to 5.99) and IBC recurrence (HR = 6.1, 95% CI = 2.5 to 14.76). Preclinical modeling in MCF10A cells demonstrated that loss of RB and PTEN impacted proliferation, motility, and invasive properties. These studies indicate that RB and PTEN together have prognostic utility and could be used to target aggressive treatment for patients with the greatest probability of benefit.

1 January 2011
Verified
Book Chapter
Closed access
PDF file
AWAgnieszka K. Witkiewicz
Agnieszka K. Witkiewicz
TWThomas C. Wright
Thomas C. Wright
AFAlex Ferenczy
Alex Ferenczy
BRBrigitte M. Ronnett
Brigitte M. Ronnett
RKRobert J. Kurman
Robert J. Kurman

18 May 2010 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
KWKaren N. Wu
Karen N. Wu
PMPeter A. McCue
Peter A. McCue
ABAdam Berger
Adam Berger
JSJoseph R. Spiegel
Joseph R. Spiegel
ZWZi-Xuan Wang
Zi-Xuan Wang
AWAgnieszka K. Witkiewicz
Agnieszka K. Witkiewicz
A 61-year-old woman presented with solitary lymphadenopathy suspicious for lymphoma. An excisional biopsy of a right inguinal lymph node demonstrated metastatic Merkel cell carcinoma (MCC). No skin lesions were detected, but a primary nasopharyngeal mass was identified. A microscopic examination of the nasopharyngeal tumor and the lymph node metastasis showed a monotonous population of small- to intermediate-sized, round blue cells with vesicular nuclei, finely granular and dusty chromatin, and multiple nucleoli. Immunohistochemistry showed perinuclear dot-like staining for cytokeratins AE1/AE3 and CK20. Microscopic appearance and immunohistochemical stains were consistent with MCC. MCC was recently shown to harbor a novel polyomavirus, Merkel cell polyomavirus (MCPyV), in the majority of cases. In this case, MCPyV was detected in the primary tumor and metastasis using polymerase chain reaction and CM2B4 immunohistochemical stain. This is the first report to demonstrate the presence of MCPyV and CM2B4 in a mucosal MCC and its metastasis.